CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2013--
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced the addition
of Paul J. Clancy, executive vice president and chief financial officer
at Biogen Idec, to the company’s board of directors.
“As the CFO of a fully integrated, large cap biotechnology company, Paul
brings invaluable experience to Agios following our successful IPO,”
said David Schenkein, M.D., chief executive officer at Agios. “We expect
that his unique perspective and relevant industry experience will be
immediately beneficial to our team, and we believe his insights as an
independent director will be particularly valuable as we continue to
mature as a company.”
Mr. Clancy has more than 20 years of experience in financial management
and strategic business planning. Mr. Clancy has served as the executive
vice president and chief financial officer at Biogen Idec since August
2007. He also served as senior vice president of finance, with
responsibilities for leading the treasury, tax, investor relations and
business planning groups. Prior to the merger of Biogen and Idec, Mr.
Clancy was the vice president of portfolio management at Biogen Inc. He
joined the company in 2001 as vice president of U.S. marketing. Before
Biogen Inc., Mr. Clancy spent 13 years at PepsiCo, serving in a variety
of financial and general management positions, including vice president
and general manager of their Great West Business Unit. Mr. Clancy has an
MBA from Columbia Business School in New York City and received his B.S.
in business administration from Babson College in Wellesley, Mass.
“Agios is seeking to build a truly differentiated company focused on
promising research in cellular metabolism with potential to transform
the lives of patients,” said Mr. Clancy. “I am looking forward to
working with David and the rest of the board and management team as they
continue in their efforts to grow and advance their programs in cancer
metabolism and inborn errors of metabolism.”
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and rare metabolic genetic diseases (known as
inborn errors of metabolism or IEMs) through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and preclinical development. All Agios programs focus on
genetically identified patient populations leveraging our knowledge of
metabolism, biology and genomics. For more information, please visit our
website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995,
including statements regarding the expected benefits of Mr. Clancy’s
service on the Board of Directors of Agios and the Company’s plans for
growth and advancement of its programs. The words “believe,” “expect”
“could,” “should,” “will,” “may” and similar expressions are intended to
identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are subject
to important risks and uncertainties that may cause actual events or
results to differ materially from Agios’ current expectations and
beliefs, including the risks described under the caption “Risk Factors”
in Agios’ Quarterly Report on Form 10-Q for the quarter ended June 30,
2013 which is on file with the Securities and Exchange Commission (SEC),
and other filings that Agios may make with the SEC in the future. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Agios expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Source: Agios Pharmaceuticals, Inc.
For Agios Pharmaceuticals, Inc.